1. Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function
- Author
-
Beatrice Gallo, Giuseppe De Rosa, Mario Marchese, Paolo Melillo, Francesco Testa, Francesca Simonelli, Valentina Di Iorio, Anna Nesti, Testa, F., Di Iorio, V., Gallo, B., Marchese, M., Nesti, A., De Rosa, G., Melillo, P., and Simonelli, F.
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Visual acuity ,Adolescent ,genetic structures ,Retinoschisis ,Visual Acuity ,X-linked retinoschisi ,030105 genetics & heredity ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Ophthalmology ,Electroretinography ,medicine ,Humans ,Carbonic Anhydrase Inhibitors ,Child ,Prospective cohort study ,Carbonic anhydrase inhibitor ,Macular edema ,Genetics (clinical) ,business.industry ,Therapeutic effect ,Retinal ,Middle Aged ,Prognosis ,medicine.disease ,eye diseases ,Acetazolamide ,chemistry ,Pediatrics, Perinatology and Child Health ,microperimetry ,030221 ophthalmology & optometry ,Female ,multifocal electroretinogram ,sense organs ,medicine.symptom ,business ,Microperimetry ,Tomography, Optical Coherence ,Retinal Dystrophies - Abstract
Background: Currently there is no medical treatment for X-linked retinoschisis (XLRS). In many retinal dystrophies, carbonic anhydrase inhibitors (CAIs) are effectively used to reduce cystoid macular edema. Prospective studies investigating the effect of CAIs in patients with XLRS are needed for the evaluation of their efficacy in this disease. The purpose of our work is to investigate the effects on macular morphology and function of oral CAIs used for the treatment of foveal lesions in patients with XLRS. Methods: Nineteen patients with a clinical diagnosis of XLRS were enrolled and prescribed oral CAIs for six months. We evaluated the therapeutic effect of CAIs with: best-corrected visual acuity (BCVA), spectral-domain optical coherence tomography, microperimetry (MP) and multifocal electroretinography (mfERG). Results: We observed a significant improvement of BCVA (p-value = 0.013), central retinal thickness (p-value = 0.004) and macular sensitivity (p-value
- Published
- 2019